Cagrilintide 10mg Prime Lab Peptides The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather Evolving Role of Double and Triple Therapy With GLP 1 Receptor Agonists in Obesity and Cardiovascular Disease ScienceDirect CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial